Schrodinger(US:SDGR)2025-02-26 21:48Financial Performance - Total revenue for 4Q24 was $88.3 million, a 19% increase compared to $74.1 million in 4Q23[13, 23] - Software revenue for 4Q24 was $79.7 million, a 16% increase compared to $68.7 million in 4Q23[13, 23] - Drug discovery revenue for 4Q24 was $8.7 million, a 58% increase compared to $5.5 million in 4Q23[13, 23] - Total revenue for FY24 was $207.5 million, a 4.2% decrease compared to $216.7 million in FY23[13, 25] - Software revenue for FY24 was $180.4 million, a 13% increase compared to $159.1 million in FY23[13, 25] - Drug discovery revenue for FY24 was $27.1 million, a 53% decrease compared to $57.5 million in FY23[13, 25] 2025 Financial Guidance - The company expects software revenue growth of 10% - 15% in 2025[13, 43] - The company expects drug discovery revenue between $45 million and $50 million in 2025[13, 43] - The company expects operating expense growth to be less than 5% in 2025[13, 43] Key Performance Indicators - Total annual contract value (ACV) increased from $154.2 million in 2023 to $190.8 million in 2024[39] - The number of customers with ACV ≥$5M doubled from 4 in 2023 to 8 in 2024[39]